Eisai Innovation and MBC BioLabs Announce 2023 Eisai Golden Ticket Competition to Accelerate Early Drug Discovery and Research Efforts
Eisai Innovation, Inc. (EII), an affiliate of Eisai Co., Ltd. the fully integrated pharmaceutical company based in Tokyo, Japan, is partnering with MBC BioLabs to award one Golden Ticket to an innovative life science startup. Eisai is interested in drug discovery platform technologies, novel targets and biology that can be utilized in oncology and neurology.
The winner of Eisai’s Golden Ticket receives:
- One-year free lab space at MBC BioLabs’ facility
- Access to the shared amenities and services provided at MBC BioLabs’ facility
- Special access to scientific and business leaders at Eisai
To apply, submit your non-confidential company presentation below. The deck should be a maximum of 10 slides and includes an appendix for any supplemental information.
Please include the following information in your company’s presentation:
- A one-page executive summary of your company
- Your company’s mission
- Key science or technology
- Targeted disease(s), patient populations or issues in healthcare
- Management Team, including advisors
- Non-confidential Intellectual Property or publications that include data supporting your science or technology
- Key milestones, including development and financing
- The competitive landscape
The deadline to apply for Eisai’s Golden Ticket is August 25, 2023.
If you have any questions, please email: GoldenTicket@eisaiinnovation.com.
About MBC BioLabs
Rent a Bench. Change the World.
MBC BioLabs is dedicated to helping life-science startups succeed. By renting space as small as a single bench and providing these entrepreneurial scientists with access to millions of dollars of equipment, we allow companies to be fast, focused, and frugal. We now have three sites: one in the Dogpatch neighborhood in San Francisco and two campuses in San Carlos. Each site has a complete molecular biology core facility that allows companies to do experiments on day one, not year one. We have partnerships with leading pharmaceutical and life-science companies as well as a built-in venture capital firm, Mission BioCapital. These partnerships provide our entrepreneurs with valuable insights about where to focus their efforts and accelerates the innovation pipeline. Our labs have truly enabled awesome: since our opening in 2013 we have helped launch and grow 230 companies. These companies have brought 54 programs to the clinic, produced 13 approved diagnostics, and raised over $7 billion.
About Eisai Innovation, Inc.
Eisai Innovation, Inc. (EII) is Eisai’s strategic investment organization aspiring to identify synergies between the scientific community and the Eisai network of companies. EII has provided equity investments to early-stage companies which develop cutting-edge drug discovery technologies, novel targets and innovative healthcare solutions. For more information about Eisai Innovation, Inc. please visit www.eisaiinnovation.com.
About Eisai
Eisai is a leading global research and development-based pharmaceutical company headquartered in Japan, with approximately 10,000 employees worldwide. We define our corporate mission as “giving first thought to patients and their families and to increasing the benefits health care provides,” which we call our human health care (hhc) philosophy. We strive to realize our hhc philosophy by delivering innovative products in therapeutic areas with high unmet medical needs, including Oncology and Neurology. In the spirit of hhc, we take that commitment even further by applying our scientific expertise, clinical capabilities and patient insights to discover and develop innovative solutions that help address society’s toughest unmet needs, including neglected tropical diseases and the Sustainable Development Goals.
For more information about Eisai, please visit www.eisai.com (for global headquarters: Eisai. Co., Ltd.), us.eisai.com (for U.S. headquarters: Eisai, Inc.) or www.eisai.eu (for Europe, Middle East, Africa, Russia, Australia and New Zealand headquarters: Eisai Europe Ltd.), and connect with us on Twitter (U.S. and global) and LinkedIn (U.S. and EMEA).
